Time(min) CCF1 CCF2 CCF3 0 0 0 0 30 64.5 ± 0.98 82.5 ± 2.2 99.00 ± 2.03 60 82.56 ± 1.12 99.16 ± 3.29 1.45 ± 2.64 120 98.32 ± 1.66 2.40 ± 1.56 2.45 ± 1.56 180 4.81 ± 0.88 4.51 ± 0.94 3.61 ± 1.17 240 6.04 ± 1.15 6.34 ± 1.12 4.53 ± 1.44 300 21.37 ± 1.63 22.87 ± 1.34 21.96 ± 1.49 360 29.74 ± 2.04 31.54 ± 1.45 31.24 ± 1.55 420 44.16 ± 1.35 47.78 ± 1.81 45.05 ± 1.33 480 56.61 ± 1.28 59.25 ± 1.65 55.46 ± 1.38 540 72.31 ± 2.53 75.36 ± 2.08 72.90 ± 2.4 600 79.00 ± 1.7 80.57 ± 1.38 80.80 ± 1.35 660 86.93 ± 0.6 89.41 ± 1.13 89.35 ± 1.11 720 97.01 ± 0.81 98.60 ± 0.84 99.43 ± 1.04

Table 9: Results of in vitro drug release of Nizatidine floating osmotic tablets with immediate release dose-compression coating (CCF1-CCF3) (n=3).